A20 prevents chronic liver inflammation and cancer by protecting hepatocytes from death

An important regulator of inflammatory signalling is the ubiquitin-editing protein A20 that acts as a break on nuclear factor-κB (NF-κB) activation, but also exerts important cytoprotective functions. A20 knockout mice are cachectic and die prematurely due to excessive multi-organ inflammation. To establish the importance of A20 in liver homeostasis and pathology, we developed a novel mouse line lacking A20 specifically in liver parenchymal cells. These mice spontaneously develop chronic liver inflammation but no fibrosis or hepatocellular carcinomas, illustrating an important role for A20 in normal liver tissue homeostasis. Hepatocyte-specific A20 knockout mice show sustained NF-κB-dependent gene expression in the liver upon tumor necrosis factor (TNF) or lipopolysaccharide injection, as well as hepatocyte apoptosis and lethality upon challenge with sublethal doses of TNF, demonstrating an essential role for A20 in the protection of mice against acute liver failure. Finally, chronic liver inflammation and enhanced hepatocyte apoptosis in hepatocyte-specific A20 knockout mice was associated with increased susceptibility to chemically or high fat-diet-induced hepatocellular carcinoma development. Together, these studies establish A20 as a crucial hepatoprotective factor.

[1]  D. Goeddel,et al.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.

[2]  N. Kabra,et al.  Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1 , 1998, Nature.

[3]  C. Kellendonk,et al.  Hepatocyte‐specific expression of Cre recombinase , 2000, Genesis.

[4]  A. Ma,et al.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. , 2000, Science.

[5]  M. Karin,et al.  Inhibition of JNK activation through NF-kappaB target genes. , 2001, Nature.

[6]  M. Karin,et al.  Inhibition of JNK activation through NF-κB target genes , 2001, Nature.

[7]  C. Ferran,et al.  A20 protects mice from D‐galactosamine/lipopolysaccharide acute toxic lethal hepatitis , 2002, Hepatology.

[8]  P. Galle,et al.  Dominant negative MORT1/FADD rescues mice from CD95 and TNF‐induced liver failure , 2003, Hepatology.

[9]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[10]  T. Kang,et al.  Caspase-8 Serves Both Apoptotic and Nonapoptotic Roles1 , 2004, The Journal of Immunology.

[11]  A. Hoeflich,et al.  Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. , 2004, Genes & development.

[12]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[13]  Matthew T Wheeler,et al.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses , 2004, Nature Immunology.

[14]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[15]  C. Ferran,et al.  A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1‐dependent mechanism , 2005, Hepatology.

[16]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[17]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[18]  S. Hübscher.  Histological assessment of non‐alcoholic fatty liver disease , 2006, Histopathology.

[19]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[20]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[21]  T. Luedde,et al.  Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma , 2007 .

[22]  D. Philpott,et al.  The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. , 2008, Immunity.

[23]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[24]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[25]  D. Lawrence,et al.  Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling , 2009, Cell.

[26]  M. Kurrer,et al.  A lymphotoxin-driven pathway to hepatocellular carcinoma. , 2009, Cancer cell.

[27]  W. Klapper,et al.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.

[28]  A. Strasser,et al.  Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. , 2009, Immunity.

[29]  S. Akira,et al.  Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis , 2009, Proceedings of the National Academy of Sciences.

[30]  Vishva Dixit,et al.  Death receptor signal transducers: nodes of coordination in immune signaling networks , 2009, Nature Immunology.

[31]  M. Pasparakis,et al.  Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor–induced toxicity and experimental colitis , 2010, The Journal of experimental medicine.

[32]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[33]  M. Pasparakis,et al.  Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor–induced toxicity and experimental colitis , 2010 .

[34]  A. Waisman,et al.  Oligodendrocyte-Specific FADD Deletion Protects Mice from Autoimmune-Mediated Demyelination , 2010, The Journal of Immunology.

[35]  J. M. Kim,et al.  Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation , 2010, Cell Death and Differentiation.

[36]  Thomas J. Fuchs,et al.  TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. , 2010, Cancer cell.

[37]  Chun-mei Wang,et al.  miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. , 2011, Biochemical and biophysical research communications.

[38]  T. Luedde,et al.  NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.

[39]  M. Campbell,et al.  Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. , 2011, Gastroenterology.

[40]  M. Bhasin,et al.  A20 Modulates Lipid Metabolism and Energy Production to Promote Liver Regeneration , 2011, PloS one.

[41]  J. Olson,et al.  A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. , 2012, Cancer discovery.

[42]  Fenggui Wei,et al.  Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells. , 2012, Biochemical and biophysical research communications.

[43]  S. Oshima,et al.  A20 Restricts Wnt Signaling in Intestinal Epithelial Cells and Suppresses Colon Carcinogenesis , 2013, PloS one.

[44]  C. Ferran,et al.  A20 promotes liver regeneration by decreasing SOCS3 expression to enhance IL‐6/STAT3 proliferative signals , 2013, Hepatology.

[45]  L. Catrysse,et al.  A20 in inflammation and autoimmunity. , 2014, Trends in immunology.

[46]  A. Zhernakova,et al.  Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. , 2014, Gastroenterology.

[47]  J. Raes,et al.  A20 controls intestinal homeostasis through cell-specific activities , 2014, Nature Communications.

[48]  Neil Kaplowitz,et al.  Cell death and cell death responses in liver disease: mechanisms and clinical relevance. , 2014, Gastroenterology.

[49]  H. Moch,et al.  Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. , 2014, Cancer cell.

[50]  C. Ferran,et al.  A20--an omnipotent protein in the liver: prometheus myth resolved? , 2014, Advances in experimental medicine and biology.

[51]  Hongyang Wang,et al.  A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression , 2015, Molecular Cancer.

[52]  Jinfeng Liu,et al.  Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation , 2015, Nature.

[53]  M. Bhasin,et al.  Significant lethality following liver resection in A20 heterozygous knockout mice uncovers a key role for A20 in liver regeneration , 2015, Cell Death and Differentiation.

[54]  K. Rittinger,et al.  LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes , 2015, Cell reports.